These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36880250)

  • 41. Measurement and treatment of agitation following traumatic brain injury: II. A survey of the Brain Injury Special Interest Group of the American Academy of Physical Medicine and Rehabilitation.
    Fugate LP; Spacek LA; Kresty LA; Levy CE; Johnson JC; Mysiw WJ
    Arch Phys Med Rehabil; 1997 Sep; 78(9):924-8. PubMed ID: 9305262
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Neurobehavioral manifestation in early period of Alzheimer disease and vascular dementia].
    Bidzan M; Bidzan L
    Psychiatr Pol; 2014; 48(2):319-30. PubMed ID: 25016769
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
    Wilcock GK; Ballard CG; Cooper JA; Loft H
    J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of standardizing care for agitation in dementia using an integrated care pathway on an inpatient geriatric psychiatry unit.
    Kumar S; Shanbhag A; Burhan AM; Colman S; Gerretsen P; Graff-Guerrero A; Kim D; Ma C; Mulsant BH; Pollock BG; Woo VL; Davies SJC; Rajji TK
    Int Psychogeriatr; 2022 Oct; 34(10):919-928. PubMed ID: 35546289
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Definition of agitation following traumatic brain injury: I. A survey of the Brain Injury Special Interest Group of the American Academy of Physical Medicine and Rehabilitation.
    Fugate LP; Spacek LA; Kresty LA; Levy CE; Johnson JC; Mysiw WJ
    Arch Phys Med Rehabil; 1997 Sep; 78(9):917-23. PubMed ID: 9305261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patterns of neuropsychiatric sub-syndromes in Brazilian and Norwegian patients with dementia.
    Truzzi A; Ulstein I; Valente L; Engelhardt E; Coutinho ES; Laks J; Engedal K
    Int Psychogeriatr; 2013 Feb; 25(2):228-35. PubMed ID: 23113901
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of agitation in Alzheimer's disease: the agitated behavior in dementia scale. Alzheimer's Disease Cooperative Study.
    Logsdon RG; Teri L; Weiner MF; Gibbons LE; Raskind M; Peskind E; Grundman M; Koss E; Thomas RG; Thal LJ
    J Am Geriatr Soc; 1999 Nov; 47(11):1354-8. PubMed ID: 10573447
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Letter to the Editor: CONVERGENCES AND DIVERGENCES IN THE ICD-11 VS. DSM-5 CLASSIFICATION OF MOOD DISORDERS.
    Cerbo AD
    Turk Psikiyatri Derg; 2021; 32(4):293-295. PubMed ID: 34964106
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Hamburg-Hannover Agitation Scale (H2A): Development and validation of a self-assessment tool for symptoms of agitation.
    Jung S; Wollmer MA; Kruger TH
    J Psychiatr Res; 2015 Oct; 69():158-65. PubMed ID: 26343608
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence of psychiatric function disorders in psychogeriatric patients at referral to nursing home care--the relation to cognition, activities of daily living and general details.
    Bakker TJ; Duivenvoorden HJ; van der Lee J; Trijsburg RW
    Dement Geriatr Cogn Disord; 2005; 20(4):215-24. PubMed ID: 16088137
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium.
    Robert PH; Verhey FR; Byrne EJ; Hurt C; De Deyn PP; Nobili F; Riello R; Rodriguez G; Frisoni GB; Tsolaki M; Kyriazopoulou N; Bullock R; Burns A; Vellas B
    Eur Psychiatry; 2005 Nov; 20(7):490-6. PubMed ID: 16310680
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms: A Cluster Randomized Controlled Trial.
    Lichtwarck B; Selbaek G; Kirkevold Ø; Rokstad AMM; Benth JŠ; Lindstrøm JC; Bergh S
    Am J Geriatr Psychiatry; 2018 Jan; 26(1):25-38. PubMed ID: 28669575
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progress in Treatment Development for Neuropsychiatric Symptoms in Alzheimer's Disease: Focus on Agitation and Aggression. A Report from the EU/US/CTAD Task Force.
    Soto M; Abushakra S; Cummings J; Siffert J; Robert P; Vellas B; Lyketsos CG;
    J Prev Alzheimers Dis; 2015 Sep; 2(3):184-188. PubMed ID: 26413494
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A review of agitation in mental illness: burden of illness and underlying pathology.
    Sachs GS
    J Clin Psychiatry; 2006; 67 Suppl 10():5-12. PubMed ID: 16965190
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia.
    Rainer MK; Masching AJ; Ertl MG; Kraxberger E; Haushofer M
    J Clin Psychiatry; 2001 Nov; 62(11):894-900. PubMed ID: 11775050
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial.
    Banerjee S; Farina N; Henderson C; High J; Stirling S; Shepstone L; Fountain J; Ballard C; Bentham P; Burns A; Fox C; Francis P; Howard R; Knapp M; Leroi I; Livingston G; Nilforooshan R; Nurock S; O'Brien J; Price A; Thomas AJ; Swart AM; Telling T; Tabet N
    Health Technol Assess; 2023 Oct; 27(23):1-108. PubMed ID: 37929672
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cognitive frailty: rational and definition from an (I.A.N.A./I.A.G.G.) international consensus group.
    Kelaiditi E; Cesari M; Canevelli M; van Kan GA; Ousset PJ; Gillette-Guyonnet S; Ritz P; Duveau F; Soto ME; Provencher V; Nourhashemi F; Salvà A; Robert P; Andrieu S; Rolland Y; Touchon J; Fitten JL; Vellas B;
    J Nutr Health Aging; 2013 Sep; 17(9):726-34. PubMed ID: 24154642
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.